Cellular Distribution of Monoclonal Antibody in Human Tumours After I.v. Administration
Overview
Authors
Affiliations
Immune-suppressed mice carrying xenografts of several different types of human germ-cell tumours were injected with a radiolabelled monoclonal antibody (LICR LON/HT13) raised against membrane components of a human germ-cell tumour (HX39). Subsequent assessment of radioactivity in excised organs and tumours showed a selective accretion of antibody in the tumour. Quantitative autoradiography supported the results of radiolocalization observed in vivo in different tumours, and also showed that the antibody localized to viable tumour cells and in close association with their cell membrane. The vascular architecture of tumours was found to be an important factor governing antibody distribution. No localization occurred with radiolabelled normal mouse IgG.
Gregoriadis G Drugs. 1982; 24(4):261-6.
PMID: 7140578 DOI: 10.2165/00003495-198224040-00001.
Moshakis V, Ormerod M, Westwood J, Imrie S, Neville A Br J Cancer. 1982; 46(1):18-21.
PMID: 7104194 PMC: 2011056. DOI: 10.1038/bjc.1982.159.
Monoclonal antibodies in the treatment of cancer: preliminary observations and future prospects.
Oldham R, Morgan A, Woodhouse C, Schroff R, Abrams P, Foon K Med Oncol Tumor Pharmacother. 1984; 1(2):51-62.
PMID: 6400033 DOI: 10.1007/BF02934975.
Antitumor monoclonal antibodies for radioimmunodetection of tumors and drug targeting.
Baldwin R, Pimm M Cancer Metastasis Rev. 1983; 2(1):89-106.
PMID: 6352009 DOI: 10.1007/BF00046907.
Radioimmunodetection of cancer: problems and potential.
Rankin E, McVie J Br Med J (Clin Res Ed). 1983; 287(6403):1402-4.
PMID: 6196075 PMC: 1549660. DOI: 10.1136/bmj.287.6403.1402.